SCHEMBL7229573

SCHEMBL7229573

COc1ccnc(-c2cccc(N=C(NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
NPFFR1 Q9GZQ6 1/20 0.39
NPFFR2 Q9Y5X5 1/20 0.39
MAPT P10636 4/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
MAPKAPK2 P49137 2/20 0.37
PLAU P00749 1/20 0.36
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
WNK1 Q9H4A3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7228914 0.91 SIGMAR1 (0.41) CCR1CCR5CCR8ACACBACACA
SCHEMBL7230300 0.90 ACACB (0.40) ACACBACACANPFFR1NPFFR2MAPT
SCHEMBL7229865 0.87 CNR1 (0.43) ACACBACACANPFFR1NPFFR2ABL1
SCHEMBL17560318 0.84 HTR3E (0.50) NPFFR1NPFFR2MAPTL3MBTL1SMN1; SMN2
SCHEMBL7238742 0.83 CCR1 (0.38) CCR1CCR5CCR8ACACBACACA
SCHEMBL7229054 0.82 MAPT (0.47) ACACBACACANPFFR1NPFFR2MAPT
SCHEMBL7230744 0.82 AAK1 (0.40) CCR1CCR5CCR8ACACBACACA
SCHEMBL7239061 0.81 AAK1 (0.41) CCR1CCR5CCR8PLAUAAK1
SCHEMBL7232327 0.81 CCR1 (0.38) CCR1CCR5CCR8PLAUABL1
SCHEMBL7240547 0.81 HRH2 (0.43) ACACBACACAMAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed